ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
 PMID: 27737783       2016       Journal of virological methods
Abstract: While raltegravir resistance profiles presented a high cross-resistance to elvitegravir, dolutegravir maintained in-vitro activity in spite of the Y143R and N155H mutations, confirming the strong activity of dolutegravir against raltegravir-resistant viruses.


  Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
 PMID: 27779200       2016       Scientific reports
Abstract: Of these 12 sequences, 11 harboured Q148H/K/R, one Y143R, and none N155H.
Introduction: With one or two major mutations, such as Q148HKR +- G140SA, <
Result: Among these sequences, Q148H/K/R mutations were found in 91.7% (N = 11) and Y143R mutation in one; yet none of them harboured an N155H mutation.


  Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
 PMID: 27532886       2016       PloS one
Abstract: The resistance of DTG is mainly shown in 13 integrase mutations (including T97T/A, E138E/D, V151V/I, N155H, Q148, Y143C/H/R, T66A and E92Q).
Abstract: The ten major integrase mutations (including N155H, Y143C/R, Q148H/R, Y143Y/H, L74L/M, E92Q, E138E/A, Y143C, Q148Q and


  HIV-1 Group O Resistance Against Integrase Inhibitors.
 PMID: 26017662       2015       Journal of acquired immune deficiency syndromes (1999)
Abstract: CONCLUSIONS: HIV-O harboring Q148R and N155H shows higher resistance to DTG compared with HIV-M subtype B.
Abstract: Site-directed mutagenesis was performed on the pCOM2.5 HIV group 0 infectious clone to ascertain the impact of INSTI resistance substitutions at positions Q148R, N155H, and R263K within integrase on susceptibility to INSTIs and infectiousness.
Abstract: The pCMO2.5/Q148R and pCMO2.5/N155H variants displayed far higher levels of resistance to DTG (>1000 FC) than was seen for group M viruses.


  Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.
 PMID: 26305833       2015       Journal of clinical virology
Abstract: A total of 141 unique mutational patterns were observed, with N155H (25.4%), Q148H (16.2%) and Y143R (8.3%) the most prevalent signature mutations.


  Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
 PMID: 25956162       2015       Antiviral research
Abstract: Our in vitro assays revealed that S119G/P/T alone exerted no effect on the susceptibility to INSTIs, whereas S119R enhanced the level of INSTI resistance induced by well-known INSTI resistance-associated mutations (Y143C, Q148H or N155H).
Abstract: The frequency of the S119X polymorphism together with Q148H/R (n=8, 63%) or N155H (n=12, 83%) was relatively high compared with that of naive group.


  Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.
 PMID: 25927004       2015       Acta naturae
Introduction: We characterized the catalytic activity of INA and its variants containing two major combinations of RALand EVG-resistance mutations: E92Q, V151I, N155H, G163R, L74M (mutant 1), and Q148K, E138K, G140S (mutant 2) .


  Dolutegravir for the treatment of HIV-2 infection.
 PMID: 25728072       2015       Journal of clinical virology
Abstract: Six out of 8 failing on raltegravir selected for integrase resistance mutations N155H (4), Y143G (1) and Q148R (1).
Abstract: Two patients bearing N155H subsequently received dolutegravir.


  HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.
 PMID: 25712318       2015       The Journal of antimicrobial chemotherapy
Abstract: At early genotyping (within 3 months of raltegravir treatment), Q148H/K/R and N155H mutations were detected regardless of the viraemia level, while Y143C/H/R was observed only in samples with viraemia >1000 copies/mL.
Abstract: At viraemia <=500 copies/mL, Q148H/K/R and N155H had the same prevalence (9.1%), while the Y143C/H/R was completely absent.


  [Resistance profile and genetic barrier of dolutegravir].
 PMID: 25858608       2015       Enfermedades infecciosas y microbiologia clinica
Abstract: Dolutegravir displays in vitro activity against mutant HIV-1 harboring any isolated resistance mutations selected during failures to raltegravir or elvitegravir (Y143C/H/, N155H, Q148H/K/R, E92G/Q, T66A/I/K, T97A, E138A/K, G140A/S).



Browser Board

 Co-occurred Entities




   Filtrator